Form 4: Nuvalent CSO Executes Pre-Planned Stock Option Transactions

Nuvalent's Chief Scientific Officer, Henry E. Pelish, executed a series of pre-planned stock option exercises and subsequent sales of Class A Common Stock totaling 3,725 shares on September 10, 2025, under a Rule 10b5-1 trading plan.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., engaged in transactions involving Class A Common Stock on September 10, 2025.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 1, 2024.
• Pelish exercised stock options to acquire a total of 3,725 shares: 731 shares at $18.93, 877 shares at $27.85, and 2,117 shares at $29.33.
• Concurrently, Pelish disposed of 3,725 shares of Class A Common Stock at a price of $78.83 per share.
• Following these transactions, Pelish's direct beneficial ownership of Class A Common Stock is 65,963 shares.
• Remaining derivative securities (stock options) include 16,637 options with an exercise price of $18.93, 25,696 options with an exercise price of $27.85, and 14,850 options with an exercise price of $29.33.

Sentiment

Score: 6

Explanation: The transactions are routine insider equity management under a pre-planned 10b5-1 plan, which generally has a neutral to slightly positive sentiment as it indicates an officer realizing value from vested options. The sale is offset by option exercises, resulting in no net change in direct ownership from these specific transactions, but a reduction in derivative holdings.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing equity rather than a reaction to immediate company news.
• The exercise of options suggests the officer is realizing value from previously granted equity, which can be a sign of long-term commitment and belief in the company's growth.
• The sale price of $78.83 is significantly higher than the exercise prices ($18.93, $27.85, $29.33), indicating a substantial gain for the officer on the exercised shares.

Negatives

• The disposition of 3,725 shares by a Chief Scientific Officer could be interpreted as a reduction in direct equity exposure, although it is offset by the option exercises, resulting in no net change in direct share count from these specific transactions.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. Such transactions are common for executives managing their equity compensation.

Stakeholder Impact

• Shareholders: Provides transparency into insider equity management, showing an officer realizing value from vested options while maintaining a significant direct stake. The pre-planned nature mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The filing details routine, pre-planned insider transactions under a Rule 10b5-1 plan. These transactions, involving the exercise of options and subsequent sale of an equivalent number of shares, are a common method for executives to manage their equity compensation and do not typically signal a change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information to warrant a change in investment thesis, suggesting a 'hold' recommendation based solely on this filing.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Chief Scientific Officer, Equity Transactions, Share Sale, Option Exercise